Ruti Aga's Six-Year Ban: Two Years for the Drug, Four for the Prescription

Hook

On Thursday the Athletics Integrity Unit (AIU) issued a statement containing three things. A date — 10 September, from which the provisional suspension ran and from which the six years will be counted. A place — a half marathon in China in March, which Ruti Aga won. And a hole — no time, no race name, no field depth, nothing. What was supplied was only the outcome.

I have an old habit, dating to 2026. Whenever a number arrives, I read the row before I read the roar. The row here is clean: two years plus four years. Two years for the substance found in her sample, four for the document manufactured to legitimise it. And the clinic named on that document did not exist.

This is where the case leaves the crowd of ordinary doping files. Aga's career was not ended by the drug. It was ended by the prescription. And for those reading "steroid" in the headlines, a technical correction is due, which I will give a full section later — methylprednisolone is not an anabolic steroid.

Context

Ruti Aga, 32, Ethiopia. Marathon. Champion at the 2026 Tokyo Marathon and three times a runner-up at World Marathon Majors. My register carries 2:18:34 for second at Berlin 2026 and 2:20:40 for the Tokyo win — both pending cross-check against the official race reports, so do not read them as final figures. That is my provenance habit, and it was built in Delhi.

At the 2026 Commonwealth Games I was a data stringer inside the Jawaharlal Nehru Stadium, logging more than 2,000 throws, Krishna Poonia's discus gold among them — India's first individual Commonwealth athletics title since Milkha Singh in 2026. Fourteen months later, CAS-confirmed doping bans fell on six Indian women athletes, several from those same 2026 relay squads. I had quoted two of them without checking a single test date. Since then every dataset I keep has a provenance column: source, test date, verification status.

In Aga's file, two of those three cells are filled. The source exists — the AIU statement. The test date has a context — that Chinese half marathon in March. Verification status? The statement is silent, and the headlines are filling the silence.

The depth of Ethiopian women's marathoning is measurable from this alone: a 2:18 athlete is not automatically selectable for a national team. The world-record tier sits at the top, and beneath it there are enough layers that the removal of one athlete is invisible at national level. That context matters, because it decides how large this ban is for the sport — roughly zero — and for Aga — total.

Core

First the technical correction, because the entire case rests on it. Methylprednisolone is a glucocorticoid — class S9 on the WADA Prohibited List — not an anabolic steroid (S1). And the S9 condition is this: prohibited in-competition only, and only by injection, oral or rectal routes. The direct implication is that this is not a "steroid use" case. It is a case about route and timing. A therapeutic knee injection is entirely lawful out of competition; it becomes a violation only if residues are present in-competition.

There is an irony here that must be read beyond the AIU statement. Aga had a legitimate defence pathway available — timing, route and medical necessity. Intra-articular methylprednisolone for knee synovitis is routine sports-medicine practice in distance runners. Had she held genuine records, the argument would have narrowed to washout intervals and administration route, and plausibly to the no-fault or no-significant-fault end. She forged the prescription instead. And at the moment she forged it, she destroyed the only defence that could have worked.

Now the arithmetic. Two years for the presence violation, four for tampering, six in total — this sits inside the Code's standard architecture. The two years signals that intent was not proven; the substance is a Specified Substance, so that is the normal period without proven intent. The four years is the Code's standard tampering sanction. Add them and you get six. What is buried in that sum is this: the panel rejected the mitigation that could have reduced the presence sanction further.

Backdating to 10 September is not a concession. Time served under provisional suspension counts against the ban — a procedural benefit, not a discount. The clock was already running where it was already running.

Now look at the verification chain on that prescription, because it is the real content of the case. Three independent verification failures, on a single sheet of paper. First: the clinic named on it did not exist. Second: the "doctor" was a family member with no medical registration. Third: he claimed to have used an old prescription pad from a former workplace, and that clinic explicitly disowned it. This is not a filing error. It is the signature of an athlete operating without a credentialed team physician.

And there is a detail most readers will skip. The four-year tampering sanction did not come from a document; it came from an interview — from statements made under questioning. A case that began with a piece of paper ended with a lie about that piece of paper.

In January 2026, when Liverpool paid £75m for Virgil van Dijk, every outlet printed the fee. I spent 72 hours on a pre/post model instead — Southampton's PPDA and aerial-duel win rate without him, Liverpool's shots faced and expected goals against. The finding was that what mattered more than the fee was the 6.4 metres of defensive line his recovery speed permitted. A transfer is not a drama, it is a delta. A ban is a delta too. Aga's pre-period: the 2026 Tokyo title, three Major second places. Post-period: nothing. And the delta runs one way only, because her next start would come at roughly 38.

What happened to that March race? The AIU statement does not state the disqualification scope, but standard practice is unambiguous: the competition at which the sample was collected is disqualified, along with its prize money, and ranking points accrued thereafter. What survives is the record before the violation date — including the 2026 Tokyo title, absent a finding of earlier use. That is the fine distinction the statement did not spell out and the headlines did not notice.

Contrarian

Now the part where I have to doubt my own row.

The substance that drew six years has no proven endurance benefit. A glucocorticoid suppresses pain and inflammation; it does not raise VO2max, does not improve oxygen carriage. When an anabolic-steroid case draws four years and a glucocorticoid case draws six, the question is not about severity of punishment but about clarity of classification. And that question will be asked from both directions — some will read this as AIU rigour, others as disproportionate enforcement against African road runners. My inclination is toward the second reading, but the data supports both, and I will not bend it to one.

Second, the thing that actually bothers me. The enforcement frontier has moved from "detection" to "document verification". Aga's case is not a lone outlier; it belongs to a recognisable family in which an initial substance violation is compounded by a fabricated explanation. When the largest share of a sanction lands on paper, the investigation goes there too — to clinic registrations, to prescription pads, to the internal consistency of a statement.

Third, and here I must be careful, because the INTJ contrarian reflex pulls me toward the most original finding, and the most original finding is usually the one that sits outside the dataset. The knee injury did not impose this ban. What imposed it was the empty medical infrastructure around the athlete — no TUE process, no credentialed team physician, nobody who could say when the injection went in and when the race was. And that is the deepest irony: with only the injury and the timing honestly documented, there may have been no case at all.

Fourth, the corner nobody connects. Large appearance-fee budgets, deep East African elite fields and the AIU's highest-yield testing ground all converge in the same Chinese label race. The fee economy and the testing economy are colliding on the same track.

Takeaway

The next case is already in the pipeline, because the same informal medical networks serve dozens of athletes in the same training clusters. What would stop it is not a sanction — it is a column that appears in no report yet: TUE status.

When the reasoned decision lands, watch three things: which race it was, what year the ban actually ends, and how far the disqualification reaches. The rest is headline.

And a question nobody has asked: of those Chinese label races, how many actually open an out-of-competition testing window? The day that count is published, this case's real value will become clear.